Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the publication of a seminal manuscript in Nature Communications, which describes a novel framework for the prediction and characterization of drug-induced liver injury (DILI), along with open-source posting of the model and validation data.